Síndrome metabólica em pacientes com diagnóstico de artrite reumatoide acompanhados em um Hospital Universitário do Nordeste brasileiro

Oliveira, Brenda Maria Gurgel Barreto de; Medeiros, Marta Maria das Chagas; Cerqueira, João Victor Medeiros de; Quixadá, Raquel Telles de Souza; Oliveira, Ídila Mont’Alverne Xavier de

doi:10.1016/j.rbr.2015.05.003

Cited by 13 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Europe the prevalence rates reported, according to criteria used were: AHA (27.4%), IDF (35.2%), IDF-AHA (37.2%) and NCEP-ATP III (23.0%)[23]. Furthermore, based on the NCE-P-ATP III criteria, Oliveira et al found that the prevalence of MetS among RA patients in South American was 51.4%, but using the IDF criteria this proportion was 53.4% [24]. Much larger differences have been reported in research from the UK, with MetS prevalence ranging from 8.2% to 42.6% [25], depending upon the definition used.…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

BackgroundEstimating the current global prevalence of metabolic syndrome (MetS), and its components, among rheumatoid arthritis (RA) patients is necessary in order to formulate preventative strategies and to ensure there are adequate community resources available for these patients. Furthermore, the association between RA and MetS is controversial and has not previously been comprehensively assessed. Therefore, the present study aimed to: 1) determine the prevalence of MetS, and its components, among RA patients across the world 2) update the odds ratio of MetS in RA patients, compared to healthy controls, using a comprehensive systematic review and meta-analysis.MethodsInternational databases, including: the Web of Science, PubMed, Scopus, Embase, CINAHL and other relevant databases were searched to identify English language articles which reported the prevalence and risk of MetS in RA patients between January 2000 and August 2016. The meta-analysis only included studies which clearly described the time and location of the study, utilised adequate sampling strategies, and appropriate statistical analyses.ResultsThe meta-analyses of prevalence (70 studies [n = 12612]) and risk (43 studies [n = 35220]) of MetS in RA patients were undertaken separately. The overall pooled prevalence of MetS was 30.65% (95% CI: 27.87–33.43), but this varied from 14.32% (95% CI: 10.59–18.05) to 37.83% (95% CI: 31.05–44.61), based upon the diagnostic criteria used. The prevalence of MetS also varied slightly between males (31.94%, 95% CI: 24.37–39.51) and females (33.03%, 95% CI: 28.09–37.97), but this was not statistically significant. The overall pooled odds ratio (OR) of MetS in RA patients, compared to healthy controls, was 1.44 (95% CI: 1.20–1.74), but this ranged from 0.70 (95% CI: 0.27–1.76) to 4.09 (95% CI: 2.03–8.25), depending on the criteria used. The mean age and diagnostic criteria of MetS were identified as sources of heterogeneity in the estimated odds ratios between studies (P<0.05).ConclusionsAccording to the high prevalence of MetS in RA patients, and high risk of MetS, measuring metabolic syndrome in RA patients is strongly recommended. Furthermore, as high waist circumference (WC) is the most common metabolic syndrome component, more attention must be paid to nutrition and weight loss among those with RA.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The findings demonstrate the difficulty in having a diagnostic criterion that is accurate, sensitive, and specific and that can be useful for assessing the general population, overcoming the limitations of regional specificities. Oliveira et al 28 showed the prevalence of MetS in the population with rheumatoid arthritis treated at the Rheumatology Outpatient Clinic of Hospital Universitário Walter Cantídio of Universidade Federal do Ceará, Ceará, Brazil, to be 53.4% by the IDF criteria and 50% by the NCEP-ATPIII criteria. Xi et al 29 used data from the China Health and Nutrition Surveys in 2009 to describe the prevalence of MetS in China and showed that the prevalence in men according to revised NCEP-ATPIII criteria for Asians was 20.9%, according to IDF criteria was 16.2%, and according to the Chinese Diabetes Society criteria was 12.2%.…”

Section: Discussionmentioning

confidence: 99%

“…In Brazil, studies estimating the prevalence of MetS for urban regions in the southeast reported 29.8% in 2007 30 and 25.4% in 2008 31 by the NCEP-ATPIII criteria, 35.5 and 46.0% in 2007 21 by the NCEP-ATPIII and IDF criteria respectively, 34.0% in 2011 32 by IDF criteria, 35.9 and 43.2% in 2011 33 by the NCEP-ATPIII and IDF criteria, respectively, and 45.2, 64.1, 69.1, and 51.9% in 2014 19 by the NCEP-ATPIII, IDF, Joint Interim Statement (JIS), and WHO criteria, respectively. According to the Brazilian region, the prevalences have been estimated as follows: in the Northeast, 50% by the NCEP-ATPIII criteria and 53.4% by the IDF criteria in 2016; 28 in the South, 50.3% by the ATPIII criteria, 53.4% by ATPIII reviewed by the AHA/NHLBI criteria, and 56.9% by the IDF criteria in 2009; 22 and in the Midwest region, 32.0% by the harmonized MetS criteria 3 in 2012. 34 In a rural population of southeastern Brazil, the MetS was found in 21.6% in 2007 35 and 14.9% in 2011 36 by the NCEP-ATPIII criteria, and in the northeastern region, the MetS was found in 24.8% by the NCEP-ATPIII criteria in 2006.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of the metabolic syndrome according to different criteria in the male population during the Blue November Campaign in Natal, RN, Northeastern Brazil

Espósito¹,

Medeiros²,

Silva³

et al. 2018

DMSO

View full text Add to dashboard Cite

BackgroundMetabolic syndrome (MetS) is an aggregation of risk factors associated with increased incidence of cardiovascular disease, type 2 diabetes mellitus, and all-cause mortality. Information on MetS prevalence is scarce in the northeast region, Brazil. This study aims to estimate the prevalence of MetS according to different diagnostic criteria in a community sample of men during the November Blue Campaign living in the metropolitan area of Natal, Rio Grande do Norte, Brazil.MethodsThis is a cross-sectional study on 500 men aged 40 years or older invited by the Blue November Campaign of 2015, an awareness program aimed at the prevention of male diseases. The evaluation included blood pressure, anthropometric measurements (weight, height, and waist circumference), fasting blood glucose, and blood lipid profile. The diagnosis of MetS was made according to the criteria of International Diabetes Federation (IDF)/American Heart Association (AHA)/National Heart, Lung, and Blood Institute (NHLBI), IDF, and National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATPIII).ResultsThe prevalence was high by considering the following three criteria: IDF/AHA/NHLBI (66.8%), IDF (60.0%), and NCEP-ATPIII (46.4%). Concordance between diagnostic criteria measured by the kappa statistic (k) was excellent between IDF/AHA/NHLBI and IDF (k=0.85, P<0.0001) and moderate between IDF/AHA/NHLBI and NCEP-ATPIII (k=0.59) and IDF and NCEP-ATPIII (k=0.54).ConclusionPrevalence of MetS in the male population was high using the three diagnostic criteria. IDF/AHA/NHLBI and IDF criteria have a high level of agreement, but NCEP-ATPIII criteria identify a lower number of MetS cases.

show abstract

“…[ 70 ] In another study in Brazil on RA patients, 110 patients with RA were evaluated and they showed a very high prevalence of MeTS markers such as abdominal obesity (98.1%), HTN (80%), and low HDL (72.2%). [ 71 ]…”

Section: Dermatologic Drug Therapy and Metabolic Syndromementioning

confidence: 99%

Skin and metabolic syndrome

Adibi

Robati

2021

Journal of Research in Medical Sciences

View full text Add to dashboard Cite

Metabolic syndrome (MeTS) is a well-known health-related problem with several end-organ damages and the resulted side effects such as rising in the blood glucose and lipid and blood pressure. Although MeTS might show several skin symptoms such as acanthosis nigricans, skin tags, acne, and androgenic alopecia, it could also be implicated in the pathophysiology of numerous dermatologic disorders. Furthermore, some dermatologic drugs might be implicated in the incidence or exacerbation of MeTS. Consequently, MeTS and skin problem could interfere closely with each other and each one could predispose the patient to the other one and vice versa. Remembering these close relationships help us to have better therapeutic choices regarding each inflammatory skin conditions. Moreover, some of the skin symptoms should be followed cautiously to define the underlying MeTS.

show abstract

Síndrome metabólica em pacientes com diagnóstico de artrite reumatoide acompanhados em um Hospital Universitário do Nordeste brasileiro

Cited by 13 publications

References 39 publications

Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis

Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis

Prevalence of the metabolic syndrome according to different criteria in the male population during the Blue November Campaign in Natal, RN, Northeastern Brazil

Skin and metabolic syndrome

Contact Info

Product

Resources

About